CDC advisory panel: senior need Prevnar 12 and Pneumovax 23
the ONA take:
According to a revised vaccination schedule recommended by the 2015 Advisory Committee on Immunization Practices (ACIP), adults 65 years and older need two pneumococcal vaccines to better protect them against a pneumococcal infection that could lead to pneumonia, meningitis, or sepsis.
Older people are at increased risk for developing a life-threatening infection by pneumococcal bacteria. Specifically, older adults are at a nearly 10 times increased risk of invasive pneumococcal disease compared with young adults.
ACIP, which is the vaccine advisory panel for the U.S. Centers for Disease Control and Prevention (CDC), recommends that people 65 years and older should receive both the Prevnar 13 and Pneumovax 23 vaccines.
Prevnar provides protection against 13 types of pneumococcal bacteria, while Pneumovax 23 protects against 23 types. The panel says that rather than only getting the vaccine that covers more types, getting both seems to provide broader protection as the two vaccines work in different ways.
If patients agree to get both vaccines, Prevnar 12 should be given first with Pneumovax 23 given 12 months later.
If a patients has already received Pneumovax 23, then the patient can receive Prevnar 12 12 months later. Because these recommendations come from the CDC's ACIP, health insurance companies, including Medicare, should cover both vaccinations for patients.
Two pneumococcal vaccines to better protect them against an infection that could lead to pneumonia, meningitis, or sepsis.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|